Serum trypsinogen-2 and trypsin-2-α1-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas

Publisher Website
Google Scholar
Abstract
Serum concentrations of trypsinogen‐2 and trypsin‐2‐α1‐antitrypsin (trypsin‐2‐AAT) were determined in 145 patients with malignant and 61 with benign digestive‐tract diseases. The validity of these tests for detection of cancer was compared with that of CA19‐9 and CEA. Elevated levels of trypsinogen‐2 (>90 μg/l) and trypsin‐2‐AAT (>25 μg/l) were found in 46% and 42%, respectively, of patients with malignant disease and the levels of trypsinogen‐2 were significantly higher than in those with benign disease (p <0.005). High trypsinogen‐2 and trypsin‐2‐AAT concentrations were found most often in patients with biliary and pancreatic cancer, but also in benign obstructive biliary disease. Our results suggest that trypsinogen‐2 and trypsin‐2‐AAT are new potential markers for cholangiocarcinomas.